CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Orchestra Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Orchestra Therapeutics, Inc.
5935 Darwin Court
Phone: 760-431-7080p:760-431-7080 Carlsbad, CA  92008  United States Ticker: OCHTQOCHTQ

This company's Plan of Liquidation went into effect on 8/18/2009
This company is no longer actively traded on any major stock exchange.

Business Summary
Orchestra Therapeutics, Inc., formerly The Immune Response Corporation, is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidate is NeuroVax for the treatment of multiple sclerosis (MS). In addition it has two product candidates, Remune and IR103, for the treatment of human immunodeficiency virus (HIV). NeuroVax, is based on the Company’s patented T-cell receptor (TCR) peptide vaccine technology. In addition to MS, the Company has open investigational new drug applications with the United States Food and Drug Administration for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. Remune and IR103 are based on the Company’s patented whole-inactivated virus technology and tested in clinical studies of Remune, the first-generation HIV product candidate of Immune Response. In July 2007, it discontinued its HIV vaccine development programme.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/200712/31/2006YesYesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Robert E.Knowling 56 2/10/2005 2/10/2005
President, Chief Financial Officer, Chief Operating Officer Michael K.Green 52 8/24/2007 10/15/2003
Vice President - Manufacturing Operations PeterLowry 45 3/1/2006
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Neuro Pharmaceuticals, Inc.
OCHTQ
Orchestra Therapeutics, Inc.
The Immune Response Corp.
The Immune Response Corporation

General Information
Number of Employees: 39 (As of 3/15/2007)
Outstanding Shares: 10,527,675 (As of 9/26/2007)
Shareholders: 370
Stock Exchange: OTC
Federal Tax Id: 330255679
Fax Number: 760-431-8636


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023